H. Osumi

Precision therapeutic strategies for advanced gastrointestinal stromal tumors

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.

Fruquintinib demonstrated feasible effectiveness and manageable toxicity in Japanese patients with mCRC and proteinuria was a major determinant of treatment feasibility and frequently led to early dose modification.

Prognostic impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer

Results show that post-treatment circulating tumor RAS and BRAF MT dynamics may serve as useful prognostic indicators, particularly with regard to BRAF MT.

Single-center Experience with Comprehensive Genomic Profiling Using Circulating Tumor DNA for Metastatic Colorectal Cancer

Re-evaluation of molecular profiles using ctDNA enabled the exploratory identification of NeoRAS wild-type patients, who could potentially benefit from anti-EGFR therapy, in a real-world setting.